WASHINGTON - The Food and Drug Administration announced Wednesday that it plans to streamline the approval process for ...

See how Teva Pharmaceutical Industries Limited's growth strategy and focus on specialty medicines are driving a turnaround.

There are three obstacles to faster development and deployment of non-addictive pain treatments. They are the business environment, the regulatory environment, and the reimbursement environment.

On October 29, 2025, the U.S. Food and Drug Administration (FDA), in coordination with the Department of Health and Human Services (HHS) and ...

Drug development pipelines are the lifeblood of the pharmaceutical industry. It is crucial for investors to understand milestones like FDA approvals and the impact of losing exclusivity on profits to ...

Duquesne Family Office's billionaire boss has gone full contrarian by selling Wall Street's two artificial intelligence (AI) ...

Study breaks down high U.S. drug pricing. — -- High prescription drug prices in the United States are largely due to drug monopolies and restrictions on price negotiations, according to a new ...

The FDA's push for lower-cost medicines looks good on paper, but the patent office under President Trump may be going in the ...

U.S. regulators approved dozens of inhalers to treat asthma and chronic obstructive pulmonary disease over a recent 15-year period, but a new study found that generic companies have only twice ...

Off-patent medicines provide people with access to high-quality essential treatment options that can be significantly less expensive than branded on-patent medicines. Off-patent therapies — generics ...

The United States has said it will speed up approval for some generic drugs. The development comes weeks after it was reported that the Trump administration had dropped its plans to impose tariffs on ...

FDA announces major reforms to streamline biosimilar approvals, potentially saving Americans billions on prescription drug ...